Secretome and degradome profiling shows that Kallikrein‐related peptidases 4, 5, 6, and 7 induce TGFβ‐1 signaling in ovarian cancer cells
暂无分享,去创建一个
Martin L. Biniossek | Oliver Schilling | Daniela Loessner | Jayachandran N. Kizhakkedathu | J. Clements | O. Schilling | V. Magdolen | J. Kizhakkedathu | M. Biniossek | Viktor Magdolen | D. Loessner | Judith A. Clements | Hasmik Shahinian | H. Shahinian
[1] E. Diamandis,et al. Human tissue kallikreins: a road under construction. , 2007, Clinica chimica acta; international journal of clinical chemistry.
[2] Raghu Kalluri,et al. The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.
[3] L. Foster,et al. Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products , 2010, Nature Biotechnology.
[4] J. Clements,et al. Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. , 2012, Gynecologic oncology.
[5] C. Heldin,et al. Regulation of EMT by TGFβ in cancer , 2012, FEBS letters.
[6] E. Diamandis,et al. Human Kallikrein 6 Degrades Extracellular Matrix Proteins and May Enhance the Metastatic Potential of Tumour Cells , 2004, Tumor Biology.
[7] Daniela Loessner,et al. Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. , 2010, Cancer research.
[8] D. Katsaros,et al. Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. , 2006, Clinical chemistry.
[9] C. Craik,et al. Specificity Profiling of Seven Human Tissue Kallikreins Reveals Individual Subsite Preferences* , 2006, Journal of Biological Chemistry.
[10] S. Mok,et al. Characterisation of human kallikrein 6/protease M expression in ovarian cancer , 2004, British Journal of Cancer.
[11] K. Shigemasa,et al. Expression of the protease inhibitor antileukoprotease and the serine protease stratum corneum chymotryptic enzyme (SCCE) is coordinated in ovarian tumors , 2001, International Journal of Gynecologic Cancer.
[12] Christopher M. Overall,et al. Factor Xa subsite mapping by proteome-derived peptide libraries improved using WebPICS, a resource for proteomic identification of cleavage sites , 2011, Biological chemistry.
[13] V. Notario,et al. The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential , 2013, Nature Reviews Cancer.
[14] P. Nelson,et al. New nomenclature for the human tissue kallikrein gene family. , 2000, Clinical chemistry.
[15] María Martín,et al. Activities at the Universal Protein Resource (UniProt) , 2013, Nucleic Acids Res..
[16] T. Reinheckel,et al. Deletion of Cysteine Cathepsins B or L Yields Differential Impacts on Murine Skin Proteome and Degradome* , 2012, Molecular & Cellular Proteomics.
[17] E. Diamandis,et al. Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines* , 2009, Molecular & Cellular Proteomics.
[18] K. Gevaert,et al. Improved visualization of protein consensus sequences by iceLogo , 2009, Nature Methods.
[19] M. Dimopoulos,et al. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] A. Scorilas,et al. Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA) , 2008, Cancer science.
[21] C. Overall,et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.
[22] D. Katsaros,et al. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] Ruedi Aebersold,et al. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry , 2003, Nature Biotechnology.
[24] D. Galileo,et al. Soluble L 1 CAM promotes breast cancer cell adhesion and migration in vitro , but not invasion , 2010 .
[25] Dietmar W Hutmacher,et al. A multiscale road map of cancer spheroids – incorporating experimental and mathematical modelling to understand cancer progression , 2013, Journal of Cell Science.
[26] R. Aebersold,et al. A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.
[27] Manfred Schmitt,et al. Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7 , 2008, Biological chemistry.
[28] C. Overall,et al. Multiplex N-terminome Analysis of MMP-2 and MMP-9 Substrate Degradomes by iTRAQ-TAILS Quantitative Proteomics* , 2010, Molecular & Cellular Proteomics.
[29] M. Matsumura,et al. Substrates of the prostate‐specific serine protease prostase/KLK4 defined by positional‐scanning peptide libraries , 2005, The Prostate.
[30] Robert Burke,et al. ProteoWizard: open source software for rapid proteomics tools development , 2008, Bioinform..
[31] J. Keski‐Oja,et al. Latent TGF-β Binding Proteins: Extracellular Matrix Association and Roles in TGF-β Activation , 2004 .
[32] R. Haun,et al. The extracellular matrix protein fibronectin is a substrate for kallikrein 7. , 2008, Biochemical and biophysical research communications.
[33] R. Leduc,et al. Processing of Transforming Growth Factor 1 Precursor by Human Furin Convertase (*) , 1995, The Journal of Biological Chemistry.
[34] E. Diamandis,et al. Human tissue kallikrein gene family: applications in cancer. , 2005, Cancer letters.
[35] H. Samaratunga,et al. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] E. Diamandis,et al. Human tissue kallikreins: physiologic roles and applications in cancer. , 2004, Molecular cancer research : MCR.
[37] L. Madisen,et al. Site-directed mutagenesis of glycosylation sites in the transforming growth factor-beta 1 (TGF beta 1) and TGF beta 2 (414) precursors and of cysteine residues within mature TGF beta 1: effects on secretion and bioactivity. , 1992, Molecular endocrinology.
[38] Robertson Craig,et al. TANDEM: matching proteins with tandem mass spectra. , 2004, Bioinformatics.
[39] R. Aebersold,et al. Mass spectrometry-based proteomics , 2003, Nature.
[40] E. Diamandis,et al. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel , 2008, British Journal of Cancer.
[41] G. Yousef,et al. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma , 2009, British Journal of Cancer.
[42] K. Shigemasa,et al. Increased Expression of Protease M in Ovarian Tumors , 1999, Tumor Biology.
[43] D. Katsaros,et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. , 2003, Cancer research.
[44] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[45] E. Diamandis,et al. Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines , 2007, Molecular & Cellular Proteomics.
[46] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[47] E. Diamandis,et al. Biochemical and Enzymatic Characterization of Human Kallikrein 5 (hK5), a Novel Serine Protease Potentially Involved in Cancer Progression* , 2005, Journal of Biological Chemistry.
[48] M. Roett,et al. Ovarian cancer: an overview. , 2009, American family physician.
[49] T. Reinheckel,et al. Contribution of cathepsin L to secretome composition and cleavage pattern of mouse embryonic fibroblasts , 2011, Biological chemistry.
[50] Tian-Li Wang,et al. Ovarian cancer specific kallikrein profile in effusions. , 2007, Gynecologic oncology.
[51] Jennifer L. Harris,et al. Defining the extended substrate specificity of kallikrein 1-related peptidases , 2007, Biological chemistry.
[52] J. Keski‐Oja,et al. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. , 2004, Critical reviews in clinical laboratory sciences.
[53] P. Altevogt,et al. EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-κB activation. , 2012, Carcinogenesis.
[54] Alexey I Nesvizhskii,et al. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.
[55] R. Kreienberg,et al. Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines , 1992, International journal of cancer.
[56] R. Aebersold,et al. Automated statistical analysis of protein abundance ratios from data generated by stable-isotope dilution and tandem mass spectrometry. , 2003, Analytical chemistry.
[57] B. R. Hoffman,et al. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker , 2002, British Journal of Cancer.
[58] A. Chalaris,et al. The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin β and ADAM10 , 2012, Cellular and Molecular Life Sciences.
[59] Erming Tian,et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy , 2004, International journal of cancer.
[60] B. Fingleton,et al. Systems-Level Analysis of Proteolytic Events in Increased Vascular Permeability and Complement Activation in Skin Inflammation , 2013, Science Signaling.
[61] J. Clements,et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. , 2005, Endocrine-related cancer.
[62] R. Aebersold,et al. Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry , 2001, Nature Biotechnology.
[63] Lennart Martens,et al. DBToolkit: processing protein databases for peptide-centric proteomics , 2005, Bioinform..
[64] Chris F. Taylor,et al. A common open representation of mass spectrometry data and its application to proteomics research , 2004, Nature Biotechnology.
[65] H. Broxmeyer,et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis , 2012, Nature Medicine.
[66] C. López-Otín,et al. Emerging roles of proteases in tumour suppression , 2007, Nature Reviews Cancer.
[67] M. Mann,et al. Trypsin Cleaves Exclusively C-terminal to Arginine and Lysine Residues*S , 2004, Molecular & Cellular Proteomics.
[68] J. Shaughnessy,et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. , 2009, Blood.
[69] G. Yousef,et al. The human kallikrein gene family: new biomarkers for ovarian cancer. , 2009, Cancer treatment and research.
[70] C. Flechtenmacher,et al. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. , 2007, Cancer research.
[71] Robert C. Bast,et al. Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis , 2004, Clinical Cancer Research.
[72] G. Yousef,et al. Tissue kallikreins: new players in normal and abnormal cell growth? , 2003, Thrombosis and Haemostasis.
[73] Dietmar W. Hutmacher,et al. Bioengineered 3 D platform to explore cell e ECM interactions and drug resistance of epithelial ovarian cancer cells , 2022 .
[74] B. Davidson,et al. Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. , 2004, Gynecologic oncology.
[75] G. Yousef,et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. , 2003, Cancer research.
[76] E. Diamandis,et al. Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins , 2006, Biological chemistry.
[77] A. Krüger,et al. Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells , 2006, Biological chemistry.
[78] Dietmar W. Hutmacher,et al. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. , 2010, Biomaterials.
[79] The UniProt Consortium,et al. Update on activities at the Universal Protein Resource (UniProt) in 2013 , 2012, Nucleic Acids Res..
[80] A. Berger,et al. Peptides of L-and D-alanine. Synthesis and optical rotations. , 1966, Biochemistry.
[81] D. Cao,et al. TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect. , 2010, Frontiers in bioscience.
[82] G. Yousef,et al. Immunofluorometric Quantification of Human Kallikrein 5 Expression in Ovarian Cancer Cytosols and Its Association with Unfavorable Patient Prognosis , 2003, Tumor Biology.
[83] W. Lau,et al. Dickkopf-1: As a Diagnostic and Prognostic Serum Marker for Early Hepatocellular Carcinoma , 2013, The International journal of biological markers.
[84] Jihun Lee,et al. Activation Profiles and Regulatory Cascades of the Human Kallikrein-related Peptidases* , 2007, Journal of Biological Chemistry.
[85] D. Katsaros,et al. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. , 2003, Clinical biochemistry.
[86] John Clarke,et al. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells , 1999, Cancer.